Aim: Neuroblastoma is a tumor with high mortality rate originating from primitive sympathetic ganglion cells. In recent years, the definition of "ultra high-risk" has been used, in which response to treatment added addition disease characteristics. this study, results tandem high-dose Iodine 131 (131I) metaiodobenzylguanidine (MIBG) and autologous hematopoietic stem cell transplantation (HSCT) ...

Neuroblastoma accounts for 8-10% of all childhood malignancies. The prognosis of neuroblastoma is highly variable depending on the age at diagnosis, stage of the disease, and tumor biology. High risk is defined as neuroblastoma occurring in children over 1 year of age with an amplification of the MYCN oncogene or distant metastasis 1) . Despite recent improvements in outcome with intensificatio...

Radiolabeled metaiodobenzylguanidine is an analog of norepinephrine used to localize tumors that express the neurohormone transporters, specifically those derived from the neural crest having a neuroendocrine origin. It is also used to treat non-surgical metastases derived from them. A review of the literature revealed symptomatic improvements associated to a decrease in hormone levels in a sig...

The present report describes the case of a woman diagnosed with an adrenocorticotropic hormone- (ACTH-) secreting thymic carcinoid associated with Cushing's syndrome. Treatment consisted of tumour resection and 131-I-meta-iodobenzylguanidine (MIBG) therapy. In spite of her iatrogenic menopausal state she twice became pregnant and delivered two healthy babies but developed recurrences during bot...

Radioiodinated meta iodobenzylguanidine (MIBG) is one of the important radiopharmaceuticals in Nuclear Medicine. [123/131I]MIBG is used for imaging of Adrenal medulla, studying heart sympathetic nerves, treatment of pheochromacytoma and neuroblastoma. For clinical application, radioiodinated MIBG is prepared through isotopic exchange method, which includes replacement of radioactive iodine in a...